Roche and Genentech have announced outcomes from the randomised, multi-centre, international Phase III SUNMO trial for those ...

Roche has demonstrated the power of combining two of oncology's hottest modalities—bispecifics and antibody-drug conjugates ...

Swiss pharma giant Roche has released encouraging results from the Phase III SUNMO study showing Lunsumio (mosunetuzumab) administered subcutaneously in combination with Polivy (polatuzumab vedotin), ...

Japan’s Otsuka has entered into an exclusive, worldwide licensing agreement with China and USA-based Harbour BioMed for the ...

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Typically, we'll ...